Zeno Equity Partners LLP Buys 12,121 Shares of Medpace Holdings, Inc. (NASDAQ:MEDP)

Zeno Equity Partners LLP grew its stake in shares of Medpace Holdings, Inc. (NASDAQ:MEDP) by 24.9% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 60,740 shares of the company’s stock after purchasing an additional 12,121 shares during the quarter. Medpace makes up 6.1% of Zeno Equity Partners LLP’s portfolio, making the stock its 9th largest holding. Zeno Equity Partners LLP owned about 0.20% of Medpace worth $20,180,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of MEDP. State Street Corp raised its stake in shares of Medpace by 7.2% in the 3rd quarter. State Street Corp now owns 752,957 shares of the company’s stock worth $251,337,000 after buying an additional 50,312 shares in the last quarter. Geode Capital Management LLC grew its holdings in shares of Medpace by 7.6% during the 3rd quarter. Geode Capital Management LLC now owns 628,054 shares of the company’s stock valued at $209,885,000 after acquiring an additional 44,371 shares in the last quarter. Wellington Management Group LLP lifted its holdings in shares of Medpace by 36.0% during the 3rd quarter. Wellington Management Group LLP now owns 415,255 shares of the company’s stock valued at $138,612,000 after buying an additional 109,886 shares during the last quarter. American Capital Management Inc. increased its stake in shares of Medpace by 2.6% during the 3rd quarter. American Capital Management Inc. now owns 380,646 shares of the company’s stock worth $127,060,000 after purchasing an additional 9,592 shares during the last quarter. Finally, GW&K Investment Management LLC raised its holdings in Medpace by 93.9% during the fourth quarter. GW&K Investment Management LLC now owns 275,460 shares of the company’s stock valued at $91,516,000 after buying an additional 133,379 shares in the last quarter. 77.98% of the stock is owned by institutional investors and hedge funds.

Medpace Stock Performance

MEDP opened at $322.93 on Wednesday. The firm has a market cap of $9.84 billion, a P/E ratio of 25.57, a PEG ratio of 3.81 and a beta of 1.47. The firm has a 50-day moving average of $339.49 and a 200 day moving average of $340.34. Medpace Holdings, Inc. has a fifty-two week low of $302.01 and a fifty-two week high of $459.77.

Medpace (NASDAQ:MEDP) last issued its quarterly earnings data on Monday, February 10th. The company reported $3.67 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.96 by $0.71. Medpace had a net margin of 19.17% and a return on equity of 51.48%. Equities research analysts predict that Medpace Holdings, Inc. will post 12.29 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Separately, Robert W. Baird raised their target price on Medpace from $354.00 to $362.00 and gave the company a “neutral” rating in a report on Monday, January 27th. Seven analysts have rated the stock with a hold rating and five have assigned a buy rating to the stock. According to MarketBeat.com, Medpace has a consensus rating of “Hold” and an average price target of $381.44.

Medpace Profile

Medpace Holdings, Inc engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance.